[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR040441A1 - TIOL COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE TO PREPARE IT AND INTERMEDIATE COMPOSITE OF UTILITY IN THIS PROCEDURE - Google Patents

TIOL COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE TO PREPARE IT AND INTERMEDIATE COMPOSITE OF UTILITY IN THIS PROCEDURE

Info

Publication number
AR040441A1
AR040441A1 AR20030102004A ARP030102004A AR040441A1 AR 040441 A1 AR040441 A1 AR 040441A1 AR 20030102004 A AR20030102004 A AR 20030102004A AR P030102004 A ARP030102004 A AR P030102004A AR 040441 A1 AR040441 A1 AR 040441A1
Authority
AR
Argentina
Prior art keywords
compound
procedure
formula
composite
manufacture
Prior art date
Application number
AR20030102004A
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0213119A external-priority patent/GB0213119D0/en
Priority claimed from GB0216856A external-priority patent/GB0216856D0/en
Priority claimed from GB0220875A external-priority patent/GB0220875D0/en
Priority claimed from GB0302543A external-priority patent/GB0302543D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR040441A1 publication Critical patent/AR040441A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de tiol que tiene la fórmula (1) en la que R1 representa alquilo C1-6; R2 representa pirazol o pirimidina, o uno de sus derivados farmacéuticamente aceptables. Composición farmacéutica que comprende un compuesto de la fórmula (1) junto con un vehículo y/o excipiente farmacéutico y uso de dicho compuesto para la fabricación de un medicamento para el tratamiento de un paciente que padece una enfermedad susceptible de ser aliviada por un inhibidor de ECA y/o EPN. Procedimiento para preparar un compuesto de fórmula (1) y compuesto intermediario de utilidad en dicho procedimiento. Reivindicación 9: Un procedimiento para preparar un compuesto de fórmula (1) según una cualquiera de las reivindicaciones 1 a 5, caracterizado porque comprende hacer reaccionar un compuesto de fórmula (2) con un compuesto de fórmula (3), seguido de desprotección en donde R1 representa alquilo C1-6; R2 representa pirazol o pirimidina; y P1 representa un grupo protector de oxígeno.A thiol compound having the formula (1) in which R 1 represents C 1-6 alkyl; R2 represents pyrazole or pyrimidine, or one of its pharmaceutically acceptable derivatives. Pharmaceutical composition comprising a compound of the formula (1) together with a pharmaceutical vehicle and / or excipient and use of said compound for the manufacture of a medicament for the treatment of a patient suffering from a disease susceptible of being relieved by an inhibitor of ECA and / or EPN. Process for preparing a compound of formula (1) and intermediate compound useful in said process. Claim 9: A process for preparing a compound of formula (1) according to any one of claims 1 to 5, characterized in that it comprises reacting a compound of formula (2) with a compound of formula (3), followed by deprotection wherein R1 represents C1-6 alkyl; R2 represents pyrazole or pyrimidine; and P1 represents an oxygen protecting group.

AR20030102004A 2002-06-07 2003-06-05 TIOL COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE TO PREPARE IT AND INTERMEDIATE COMPOSITE OF UTILITY IN THIS PROCEDURE AR040441A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0213119A GB0213119D0 (en) 2002-06-07 2002-06-07 Compounds
GB0216856A GB0216856D0 (en) 2002-07-19 2002-07-19 Compounds
GB0220875A GB0220875D0 (en) 2002-09-09 2002-09-09 Compounds
GB0302543A GB0302543D0 (en) 2003-02-04 2003-02-04 Compounds

Publications (1)

Publication Number Publication Date
AR040441A1 true AR040441A1 (en) 2005-04-06

Family

ID=29740912

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102004A AR040441A1 (en) 2002-06-07 2003-06-05 TIOL COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE TO PREPARE IT AND INTERMEDIATE COMPOSITE OF UTILITY IN THIS PROCEDURE

Country Status (4)

Country Link
AR (1) AR040441A1 (en)
AU (1) AU2003232941A1 (en)
TW (1) TW200407310A (en)
WO (1) WO2003104200A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786119B2 (en) 2004-04-01 2010-08-31 Cardiome Pharma Corp. Drug conjugates of ion channel modulating compounds
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7855291B2 (en) 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
CN101351451B (en) 2005-12-29 2013-02-20 莱西肯医药有限公司 Multicyclic amino acid derivatives and methods of their use
BRPI0815754B1 (en) 2007-08-24 2022-03-22 Tersera Therapeutics Llc METHODS TO PREPARE COMPOUNDS BASED ON 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE AND INTERMEDIATE COMPOUND
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
TN2016000031A1 (en) 2013-07-25 2017-07-05 Novartis Ag Cyclic polypeptides for the treatment of heart failure
KR20160031552A (en) 2013-07-25 2016-03-22 노파르티스 아게 Bioconjugates of synthetic apelin polypeptides
CR20170338A (en) 2015-01-23 2017-09-12 Novartis Ag CONJUGATES OF FATTY ACIDS AND SYNTHETIC APPEAL WITH GREATER HALF LIFE
WO2020110011A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
JP2022507958A (en) 2018-11-27 2022-01-18 ノバルティス アーゲー Cyclic tetramer compound as a proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor for the treatment of metabolic disorders
UY38485A (en) 2018-11-27 2020-06-30 Novartis Ag CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION
TW202333563A (en) 2021-11-12 2023-09-01 瑞士商諾華公司 Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277737B1 (en) * 1995-12-28 1997-11-12 Zambon Spa TIOLIC DERIVATIVES FOR METALLOPEPTIDASE INHIBITIVE ACTIVITY
US5760241A (en) * 1995-12-28 1998-06-02 Zambon Group S.P.A. Thiol derivatives with metallopeptidase inhibitory activity

Also Published As

Publication number Publication date
AU2003232941A1 (en) 2003-12-22
WO2003104200A1 (en) 2003-12-18
TW200407310A (en) 2004-05-16

Similar Documents

Publication Publication Date Title
AR040441A1 (en) TIOL COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE TO PREPARE IT AND INTERMEDIATE COMPOSITE OF UTILITY IN THIS PROCEDURE
BRPI0409227B8 (en) "compound, pharmaceutical composition, use of a compound and process for the preparation of a compound of formula (i)"
BRPI0720551A2 (en) compound or a pharmaceutically acceptable salt thereof, and, use thereof, method for treating cancer, processes for preparing a pharmaceutical composition and a compound or a pharmaceutically acceptable salt thereof
CY1109422T1 (en) PHENATHANOLAMIN PRODUCTS FOR TREATMENT OF RESPIRATORY DISEASES
DE60336664D1 (en) NONNUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
BRPI0418251B8 (en) phosphonates, monophosphonamidates, bisphosphonamidates, and pharmaceutical composition comprising them
BR0010555A (en) Neuraminidase Inhibitors
ATE361287T1 (en) NEW INDOL-2-ON DERIVATIVES
EA201000643A1 (en) SUBSTITUTED PRODUCTION OF ETHYLENEDIAMIN FOR THE TREATMENT OF MYCOBACTERIAL DISEASES AND PHARMACEUTICAL COMPOSITION ON ITS BASIS
AR054129A1 (en) DERIVATIVES OF 2, 6-QUINOLINILO, A PHARMACEUTICAL PREPARATION THAT CONTAINS THEM AND ITS EMPLOYMENT IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DEPENDENT DISEASES OF INTEGRINES ALFA4BETA1 AND / OR ALFA4BETA7
BR0315580A (en) Methylene Urea Derivatives
PA8432901A1 (en) PIRIDILPIRROL COMPOUNDS
BRPI0409627A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
SE0302192D0 (en) Novel compounds
CY1109013T1 (en) NEW 4,4΄-DYPHYTHODES- (3-AMINOBUTANIUM-1-SULPHONIC) PRODUCTS AND COMPOSITIONS CONTAINING THEM
BRPI0409427A (en) compound, use thereof, pharmaceutical composition, method of treating a human suffering from a hyperproliferative disease, and process for the preparation of a compound or a pharmaceutically acceptable salt, ester or prodrug thereof
BRPI0416287A (en) compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for the treatment and / or prevention of diseases that are modulated by accß inhibitors and their use
ATE386725T1 (en) HETEROCYCLYL COMPOUNDS
GB0109122D0 (en) Novel compounds
ATE259795T1 (en) CARBOXIC ACIDS AND ACYLSULFONAMIDES, PREPARATIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHODS
MX2022015554A (en) Small molecule modulators of il-17.
FR2850023B1 (en) DRUGS FOR THE NERVOUS SYSTEM
BR0314352A (en) 2,7-substituted indols and their use as 5-ht6 modulators
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal